f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology

First Page		Document Content
Date: 2014-06-26 13:56:08 Mesothelin Proteins Mesothelioma Ira Pastan Cancer vaccine Management of cancer Chemotherapy Anti-CD22 immunotoxin Medicine Health Cancer treatments		f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology Add to Reading List Source URL: home.ccr.cancer.gov Download Document from Source Website File Size: 2,66 MB Share Document on Facebook

	A Better Immunotoxin Through inspired engineering, proteins that enter and kill cancer cells are finding their place among cancer treatments. (Photo: R. Baer) DocID: Gf5A - View Document
	f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology DocID: C35z - View Document
	f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology DocID: AXqR - View Document
	Chapter 19 The Preclinical and Clinical Evaluation of VB6845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors Joycelyn Entwistle, Mark Kowalski, Jennifer Brown, DocID: zxDe - View Document
	PDF Document DocID: wF5F - View Document